linjc16/ctgov huggingface dataset:
Determination of Propofol Target Concentration for Young and Elderly by Suppression Rate Analysis

Study Overview
=================
Brief Summary
-----------------
Propofol's dose-response curve is know for the average adult but propofol's plasmatic concentration under total intravenous anesthesia differences between young and elderly must be modeled. Adaptative clinical trial (Dixon's Up and Down) for determination of ED95% of propofol concentration for hypnosis under general anesthesia for young and elderly adults.

Detailed Description
-----------------
Propofol's dose-response curve is know for the average adult but propofol's plasmatic concentration under total intravenous anesthesia differences between young and elderly must be modeled. Method: adaptative clinical trial (Dixon's Up and Down method) for determination of ED95% of propofol concentration (plasmatic, Marsh model) for hypnosis (BIS ranging from 40 to 60) under general anesthesia for young and elderly adults.

Official Title
-----------------
Determination of Propofol Target Concentration for Young and Elderly by Suppression Rate Analysis

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Drug: Propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both sex Between 18-28 or 65-75 years old ASA physical status I or II no pre-anesthetic medications prescribed scheduled for surgery under general anesthesia willing to participate and sign informed consent. Exclusion Criteria: Contraindications for propofol usage history of neurologic or psychiatric diseases drug abusers users of drugs that alter central nervous system pregnancy emergency surgeries rapid sequence intubation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Study Arm<br>All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose. | Drug: Propofol<br>* Propofol plasmatic concentration (Marsh)<br>* Other names: Diprivan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| BIS value greater than 60 or lower than 40 during general anesthesia | BIS value greater than 60 or lower than 40 during general anesthesia | BIS value greater than 60 or lower than 40 during general anesthesia | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
propofol, dose-response, elderly, young adults
Acute STROke Complicating TAVI - Management and Outcomes

Study Overview
=================
Brief Summary
-----------------
Periprocedural complications of trans catheter aortic valve implantation, and particularly the occurrence of stroke has a marked impact on survival and quality of life. The characteristics of periprocedural stroke complicating TAVI, and particularly of interventions aimed to treat stroke complicating TAVI have not been systematically described. We therefore aimed is to explore the incidence and characteristics of acute stroke complicating TAVI and to describe the safety and efficacy of emergent interventions to treat acute stroke complicating TAVI.

Official Title
-----------------
Management and Outcomes of Acute STROke Complicating Transcatheter Aortic Valve Implantation

Conditions
-----------------
Stroke, Aortic Valve Stenosis, Periprocedural Complication

Intervention / Treatment
-----------------
* Procedure: Mechanical thrombectomy
* Drug: Thrombolytic Agent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who have had a stroke within 30 days of TAVI Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Conservative treatment<br>patients with periprocedural stroke after TAVI, treated conservatively | |
| Neuro-intervention<br>patients with periprocedural stroke after TAVI, treated with neuro-intervention | Procedure: Mechanical thrombectomy<br>* Percutaneous intervention aimed to retrieve/treat clot affecting the cerebral circulation.<br>Drug: Thrombolytic Agent<br>* Drug aimed to dissolve thrombus affecting the cerebral circulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause mortality | All cause death | 1-year | 
| Neurologic disability free survival | modified rankin score (mRS) 0/1 | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding complications | Severe bleeding / life-threatening bleeding as defined by VARC2 criteria | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
periprocedural stroke, transcatheter aortic valve implantation, transcatheter aortic valve replacement
Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines

Study Overview
=================
Brief Summary
-----------------
This study aims to compare the effects of local wound infiltration with ketamine versus dexmedetomidine when added to bupivacaine on inflammatory cytokine response after total abdominal hysterectomy.

Official Title
-----------------
Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy

Conditions
-----------------
Endometrial Adenocarcinoma

Intervention / Treatment
-----------------
* Drug: Ketamine
* Drug: dexmedetomidine
* Drug: bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II patients age range (18-60) years, weight (50- 90) kg Exclusion Criteria: allergy to study drugs significant cardiac disease respiratory disease renal disease hepatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ketamine<br> | Drug: Ketamine<br>* patients receive local anesthetic wound infiltration with 1 mg /kg ketamine<br>|
| Active Comparator: dexmedetomidine<br> | Drug: dexmedetomidine<br>* patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine<br>|
| Placebo Comparator: bupivacaine<br> | Drug: Ketamine<br>* patients receive local anesthetic wound infiltration with 1 mg /kg ketamine<br>Drug: dexmedetomidine<br>* patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine<br>Drug: bupivacaine<br>* patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| severity of pain at rest and on coughing | severity of pain at rest and on coughing will be assessed using a 10-cm Visual Analog Scale (0 = no pain and 10 = worst imaginable pain) | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sedation | sedation by using sedation score | 24 hours |
Patellar Resurfacing in Total Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
Background: The best treatment of the patella during total knee arthroplasty (TKA) is controversial. The implantation of a patellar component adds to the operation time and the costs of the operation.There is a huge variation as to whether the patella is resurfaced or not during TKA. Meta-analysis of prospective, randomised trials might indicate that patellar resurfacing reduces the risk of reoperation and anterior knee pain, but drawing firm conclusions is not possible and additional, high quality randomised trials are required. Purpose: The aim of this study is to determine whether ther is a difference between the two groups in knee pain, functions, patient satisfaction and quality of life after TKA.

Official Title
-----------------
Patellar Resurfacing in Total Knee Arthroplasty. A Prospective, Randomised and Double Blind Study.

Conditions
-----------------
Osteoarthritis, Pain

Intervention / Treatment
-----------------
* Procedure: Patellar component
* Procedure: No patellar component


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients less than 85 years old with osteoarthritis scheduled for primary knee arthroplasty. Exclusion Criteria: Patients who are not able to cooperate Serious deformity (not suitable for a standard CR prosthesis) Patellar thickness less than 18 mm Prior operation involving the extensor mechanism Rheumatoid arthritis Severe medical disability limiting the ability to walk Revision surgery Knees with predominantly patellofemoral arthrosis

Ages Eligible for Study
-----------------
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Patellar resurfacing | Procedure: Patellar component<br>* Resurfacing with onlay technique<br>|
| Active Comparator: 2<br>Patellar retention | Procedure: No patellar component<br>* Trimming of osteophytes when appropriate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee injury and Osteoarthritis Outcome Score |  | 3 years follow up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oxford score, Knee Society score, Stair climbing test, Pain (VAS), Patient satisfaction (VAS) |  | 3 years follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Replacement, Knee, Patella, Arthroplasty
Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples

Study Overview
=================
Brief Summary
-----------------
Cancer results when undifferentiated cells grow in an uncontrolled manner, crowding out normal cells, causing morbidity and ultimately mortality. The cancer stem cell theory suggests that most tumors undergo a process of differentiation through which a relatively rare cancer stem or progenitor cell (CSC) gives rise to more differentiated populations of cells (including transiently amplifying cells) comprising the bulk of the tumor. As a result of this cellular diversity, one or more cells within the tumor are likely to be resistant to therapy. Among cells resistant to a given therapy, only CSCs can repopulate the tumor. A key feature of this resistant subset of CSCs is that they repopulate a tumor resistant to the original intervention. The cellular programs driving the uncontrolled proliferation of many solid tumors result from aberrant activity of Wnt, Shh, and/or Notch signaling pathways in CSC. Thus, therapies that down-regulate the activity of these fundamental pathways in CSCs will be effective in the treatment of cancer. The investigators' research program focuses on the elucidation of signaling mechanisms, control of cellular processes and discovery of small molecules that selectively target Wnt, Shh, and Notch signaling pathways that are fundamental to CSCs. Our preliminary results identified a novel Notch associated protein NACK that functions as a transcriptional co-activator of Notch. Moreover, Nack is expressed in human solid tumors and is required for cell survival and tumor growth in notch -dependent tumor cells. The investigators' aim is to further interrogate the link between Notch and Nack.

Official Title
-----------------
Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with a primary cancer tumor scheduled for a surgery to remove it. Exclusion Criteria: Patients not diagnosed with a primary cancer scheduled for a standard of care (SOC) surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify and isolate the cancer stem cell populations from primary tumor samples. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wnt, Notch, Hedgehog, Tumor Sample
Clinical Analysis of Two Toric Intraocular Lenses

Study Overview
=================
Brief Summary
-----------------
Purpose: Comparison of two torical intraocular lenses with differents haptic design in patients with cataract. Methods: In this prospective, randomized clinical trial 120 eyes of 60 patients underwent phacoemulsification. In patient's eyes the Tecnis torical IOL (Abbott Medical Optics) or the AT Torbi torical 709 MB IOL (Zeiss Medical AG) were randomly implanted. Three months after surgery visual acuity, rotation stability and astigmatism correction were evaluated.

Official Title
-----------------
Comparison of Two Toric IOL´s With Different Haptic Design: Optical Quality After 1 Year

Conditions
-----------------
Cataract, IOL

Intervention / Treatment
-----------------
* Device: intraocular lenses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age related cataract on both eyes Corneal astigmatism 1,0- 4,0 D Potential postoperative visus 1,0 No other ocular pathology as cataract Age 18 - 80 Written informed consent to surgery and participation in the study Exclusion Criteria: Pregnancy, breastfeeding Amblyopy, diabetic retinopathy, uveitis or other relevant ophthalmologic diseases Optical media disturbances due to: corneal and vitreal opacity, PEX Irregular astigmatism measured with corneal topography (Visante-omni), keratoconus ≥ 10 degrees difference between the axis of keratometry measurement of the IOL Master and the simulated K reading of the corneal topograph (Visante-omni) Trauma, ocular surgery performed within 6 months Traumatic cataract Potential postoperative visus under 1,0

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 2 different torical intraocular lenses<br> | Device: intraocular lenses<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uncorrected visual acuity | visual acuity in logMARon an ETDRS Chart | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
toric IOL
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.

Official Title
-----------------
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Conditions
-----------------
HIV Infections, Leukoplakia, Hairy

Intervention / Treatment
-----------------
* Drug: Acyclovir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Concurrent Medication: Allowed: Topical antifungal therapy. Patient must have: Newly diagnosed clinical and histological hairy leukoplakia. Positive HIV antibody by licensed ELISA or Western blot. Exclusion Criteria Co-existing Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Concurrent Medication: Excluded within 2 weeks of study entry: Systemic antifungal treatment. Excluded within 6 weeks of study entry: Immunomodulators. Systemic antiviral treatment. Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Prior Medication: Excluded within 2 weeks of study entry: Systemic antifungal. Excluded within 6 weeks of study entry: Immunomodulators. Systemic antiviral treatment. Excluded within 8 weeks of study entry: Zidovudine (AZT) or other antiretroviral therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Acyclovir|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS-Related Opportunistic Infections, Leukoplakia, Oral, Herpesvirus 4, Human, Acyclovir, AIDS-Related Complex
Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine on preliminary basis weather an elevated pro-calcitonin level can be used to assess ischemia as a result of coronary artery complications during percutaneous coronary intervention (PCI).

Detailed Description
-----------------
Pro-calcitonin is a type of protein found in the blood. This protein has recently be found to be elevated in patients with diseases of the arteries of the heart such as heart attack. Percutaneous coronary intervention (PCI) is widely used in the treatment of many patients with blockage in the arteries of the heart. the investigators normally used a marker called troponin after cardiac catheterization. However, this marker may not be specific. Pro-calcitonin has been found to be a useful marker for the detection of myocardial injury. the value of Pro-calcitonin as a marker for the identification of myocardial damage undergoing PCI has not yet been studied.

Official Title
-----------------
Utility of Pro-calcitonin as an Indicator of Ischemia in Patients Undergoing Percutaneous Coronary Intervention With Subsequent Coronary Complications.

Conditions
-----------------
Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients older than 18 years old. Exclusion Criteria: no consent. suspicion of sepsis. Patients with elevated troponin or procalcitonin before enrollment. patients who had non-elective angioplasty (e.g. rescue angioplasty, primary angioplasty, salvage angioplasty, or emergency angioplasty)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| coronary complication<br>patients with coronary complication and patients without coronary complications. pro-calcitonin will be measured in both groups to see if any correlation. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pro-calcitonin blood level |  | 0,24 hours post cardiac intervention |